Pentraxin-3 (PTX3), an acute-phase protein released during inflammation, aids phagocytic clearance of pathogens and apoptotic cells, and plays diverse immunoregulatory roles in tissue injury.. Previously we showed a strong TLR2-mediated induction of PTX3 in cultured human microglia and macrophages by HspB5, which accumulates in glia during MS. Given the anti-inflammatory effects of HspB5, we examined the contribution of PTX3 to these effects in MS and its animal model EAE. Our data indicate that TLR engagement effectively induces PTX3 expression in human microglia, and that such expression is readily detectable in MS lesions. Enhanced PTX3 expression is prominently expressed in microglia in preactive MS lesions ,and in microglia/macrophages engaged in myelin phagocytosis in actively demyelinating lesions. Yet, we did not detect PTX3 in cerebrospinal fluid of MS patients. PTX3 expression is also elevated in spinal cords during chronic relapsing EAE in Biozzi ABH mice, but the EAE severity and time course in PTX3-deficient mice did not differ from WT mice. Moreover, systemic PTX3 administration did not alter the disease onset or severity. Our findings reveal local functions of PTX3 during neuroinflammation in facilitating myelin phagocytosis, but do not point to a role for PTX3 in controlling the development of autoimmune neuroinflammation.
Introduction
Pentraxin-3 (PTX3) is a member of the pentraxin superfamily, a group of acute phase proteins sharing the pentraxin domain, a cyclic multimeric structure with a conserved eight amino acid sequence in the C-terminus [1] [2] [3] . Pentraxins are key components of the humoral arm of innate immunity 1 . The pentraxin superfamily includes the classical short pentraxins such as C-reactive protein (CRP) and serum amyloid P component (SAP), and the long pentraxins to which PTX3 belongs 3 . In contrast to the short pentraxins, PTX3 is not produced and secreted by the liver, but it is produced locally at the site of inflammation 4 . In response to several inflammatory stimuli including TLR engagement or exposure to pro-inflammatory cytokines, PTX3 is rapidly released by various cell types, in particular neutrophils, macrophages, microglia, dendritic cells, fibroblasts and endothelial cells 5, 6 . PTX3 fulfils an important pattern-recognition function, binding with high affinity to several different viruses, bacteria and fungi 7, 8 . Such binding promotes destruction and clearance of these pathogens by engaging C1q and activation of the classical complement pathway 2, 9 . A similar clearance function also applies to apoptotic cells to which PTX3 binds, thus assisting their removal by phagocytes 6, 10, 11 . Apart from fulfilling the above antibody-like functions, PTX3 also plays a role in regulating inflammatory pathways. However, the role of PTX3 during neuroinflammation remains poorly understood. PTX3 mediates neurogenesis and resolves oedema in experimentally-induced ischemia in the central nervous system (CNS) 12 . PTX3-deficient mice develop more severe tissue damage in experimental models of kainate-induced seizures or ischemic brain injury, and also in experimental cardiac ischemia, and during both acute and chronic kidney injury 13, 14 . While PTX3 has antiviral effects 8 another activity of PTX3 that is likely relevant in this context of immune-mediated disorders is its ability to inhibit leukocyte recruitment into tissues by binding to P-selectin that promotes leukocyte rolling prior to extravasation 7 . PTX3 also modulates phagocytic activity of microglia this could play a role in the clearance of CNS tissue debris, which is essential for adequate recovery after damage 15, 16 . In the case of damaged neurons, PTX3 binding helps rescue them from irreversible damage and phagocytic clearance 14, 17 . However, other data point to a possible pathogenic role of PTX3 in neuroinflammation although such levels could indicate that PTX3 merely reflects severity. For example high plasma levels of PTX3 are associated with increased mortality after stroke in humans 12 and with aggravated optic nerve damage in mice 18 . Also, in humans infected with chikungunya or Ross River virus elevated levels PTX3 in serum are associated with increased viral load and more severe clinical disease 19 . Likewise, in acute EAE, the animal model for MS, levels of PTX3-encoding transcripts are increased in the spinal cord early in disease, and they remain high despite cessation and recovery from neurological disease 20 . Correspondingly, PTX3 levels are increased in the plasma of MS patients during a relapsing stage 21 suggesting PTX3 might orchestrate recovery. Much, however, remains to be clarified about the role of PTX3 during neuroinflammation.
In this study, we examined the possible role of PTX3 in neuroinflammatory conditions, focusing on MS and its animal model EAE 22 . MS is characterized by disseminated areas of demyelination and inflammation throughout the CNS. Before any signs of myelin damage appear, small clusters of activated microglia frequently emerge in the normal-appearing white matter (NAWM) 23 . In vivo imaging studies have shown that these so-called preactive lesions can precede the appearance of an actively demyelinating MS lesion in the same location by several months 24, 25 . Yet, current data suggest that preactive MS lesions represent an initial, but reversible stage in lesion development, and that most of them resolve without causing subsequent damage 23, [26] [27] [28] . Preactive lesions are not associated with blood-brain barrier damage or leukocyte infiltration, suggesting that their development is triggered by an endogenous factor. One candidate factor is the HspPB5, which accumulates in stressed oligodendrocytes that are invariably associated with preactive lesions 26, 29 . Since HspB5 acts as a TLR2 agonist and uses CD14 as an essential co-receptor, it is a selective activator of microglia, macrophages and monocytes 30, 31 . Recent transcript profiling studies have revealed that the HspB5-induced response in human microglia and macrophages is dominated by immune-regulatory, anti-inflammatory and anti-viral factors, and that an up to 95-fold increase in PTX3 transcripts is one of the most prominent elements in this response program 30, 31 . This finding prompted us to more closely evaluate PTX3 expression in the CNS during lesion development in MS, examine other potential triggers for its expression, and evaluate its presence as a soluble factor in samples of plasma and cerebrospinal fluid (CSF). Furthermore, we compared clinical and histological features of EAE between PTX3-deficient and WT mice, and examined the effects of therapeutic administration of recombinant PTX3 on the course of disease. Together, our data are in line with the idea that PTX3 is triggered by a local TLR response, but they do not present a strong case for an immune-regulatory role of PTX3 during the early stages of autoimmune neuroinflammation.
Materials & Methods

Autopsy material
Post-mortem human brain tissue samples were obtained in collaboration with the Netherlands Brain Bank (coordinator Dr. I. Huitinga), following approval by local legal and ethical committees. All patients and control donors had given informed consent for autopsy and the use of brain tissue for research purposes. Patient details are listed in Supplementary Table 1.
Mice
Female and male Biozzi ABH (H-2dq1) were bred from stock at QMUL, London, UK. WT C57BL/6 (H-2b) mice, heterozygous mice (PTX3+/-), and C57BL/6 with a null mutation in the PTX3 gene (PTX3-/-) were bred at IRCCS Humanitas Clinical and Research Centre, Milan and transferred to the Clinical Neuroimmunology Unit San Raphael, Milan for the EAE studies.
All procedures were performed following institutional ethical review in accordance to the United Kingdom Animals (Scientific Procedures) Act (1986) and European Union Directive 2010/63/EU. Animals were housed and monitored as described previously 32 . The studies adhere to the ARRIVE guidelines 33 .
EAE induction and neurological disease assessment C57BL/6 mice Female C57BL/6 mice (WT; n=8), PTX3-deficient mice (PTX3-/-; n=10) and heterozygous mice (PTX3+/-; n=7) aged 6-8 wks were immunized by subcutaneous injection under the rostral part of the flanks and at the base of the tail with 300µl PBS containing 200µg of the murine myelin oligodendrocyte glycoprotein peptide 35-55 (MOG ; Espikem, Florence, Italy) in incomplete Freund's adjuvant (IFA; Sigma-Aldrich, Milan, Italy) containing 4mg/mL Mycobacterium tuberculosis (strain H37Ra; Difco Laboratories Inc., Franklin Lakes, NJ, USA) to make CFA. Pertussis toxin (Sigma; 500ng) was injected intraperitoneally on the day of the immunization and again two days later, as described previously 34 . Body weight and clinical scores (0 = healthy; 1 = limp tail; 2 = ataxia and/or paresis of hind limbs; 3 =paralysis of hind limbs and/or paresis of forelimbs; 4= tetraplegia; 5 = moribund or dead) were recorded daily by an investigator blinded to group identity. Clinical signs that were less severe than typically observed were scored 0.5 less than the indicated grade.
Biozzi ABH mice
Mouse spinal cord homogenate (SCH) was lyophilized and reconstituted in PBS prior to use as previously described 32 . Briefly, SCH dissolved in PBS was emulsified 1:1 with CFA i.e. 320µg/mL M. tuberculosis and 40µg/ml M. butyricum in IFA (Difco Laboratories, Detroit, MI). Mice (n=30) were injected subcutaneously on days 0 and 7 with 300µl emulsion divided over two spots on the flanks. Mice were weighed and scored daily for neurological signs as described above. On day 7, mice were randomly divided into three groups and injected intravenously on days 10,12 and 14 with 100µL PBS containing 1mg/mL recombinant glycosylated human PTX3 (Group A; n=10) or with vehicle (PBS) alone (Group B; n= 10). As a positive control (Group C) mice were treated with 250µg CD4-depleting (YTS191.1) monoclonal antibody (Bio X cell, New Hampshire, USA) on day 12 and 2x107 SCH coupled splenocytes injected intravenously on day 19 as described previously 32 . We have previously shown this immunological tolerance to be effective in blocking clinical signs of EAE in Biozzi ABH mice 35 .
Immunohistochemistry
Cryosections (5µm) from human brain tissues from 13 MS patients (20 blocks) and 4 control subjects (4 blocks) or from the mice sacrificed were fixed in acetone or 2% formalin (PLP staining) for 10min and rinsed in PBS. Endogenous peroxidase was quenched with 0.3% H2O2. Sections were blocked with 5% normal goat serum in PBS (containing 2% human serum, in case of human sections) or CleanVision (Immunologic, Duiven, The Netherlands) when primary mouse antibodies were used on mouse tissue. Subsequently, human slides were incubated overnight with primary antibodies directed to proteolipid protein (PLP), HLA-DR or PTX3, while mouse sections were incubated with anti-PLP, -iba1, -GFAP and -CD3 (Table1), diluted in antibody diluent™(Immunologic). After washing, appropriate HRP-labeled-secondary antibodies were applied for 1h and staining was visualized with DAB (Dako). Slides were counterstained with haematoxylin, dehydrated and mounted with Quick D (Klinipath, Duiven, The Netherlands). To detect foamy macrophages/microglia slides were incubated with 0.5% ORO in isopropanol for 15min and differentiated in isopropanol. After which sections were counterstained with haematoxylin and mounted with Aquatex (Millipore, Billerica, MA). Pictures of regions of interest were taken with a Leica DC500. 
Double immunolabelling
Sections were prepared as described above and antibodies directed to PTX3 and HLA-DR (activated microglia) or glial fibrillary acidic protein (GFAP; astrocytes) were incubated simultaneously overnight at RT. Fluorescent labeled secondary antibodies were used to visualize primary antibody binding. Sections were incubated with Sudan black (Sigma-Aldrich, St Louis, MO) to reduce background staining and nuclei were visualized with DAPI (Invitrogen, Paisley United Kingdom). Sections were mounted with FluorPreserveTM (Millipore) and pictures were taken with a Leica DM 5500 using software LAS-AF 3.0.0 and processed with ImageJ. Mice cryosections were stained with antibodies directed to PTX3 as described above, after which slides were incubated with antibodies directed against iba1 or GFAP for 1h. Alkaline phophatase (AP) labeled secondary antibodies were applied after intensively rinsing. Visualization of AP labelling was done with liquid permanent red (Dako). To allow the two rabbit primary antibodies to double stain, sections were treated in EDTA (pH 9) at 90°C for 30 min after the PTX3-staining.
Isolation and culture of human adult microglia
Human microglia were isolated as described by Peferoen et al 28 . In short, 10g of white matter was digested in 0.25% (w/v) trypsin (Sigma-Aldrich) and purified through a 100-µm nylon mesh (Biosciences, Durham, NC). Myelin and cell debris were removed by 30% Percoll gradient centrifugation. Erythrocytes were lysed with 8.3 g/L of NH4Cl (Merck) and 1 g/L of KHCO3 (Merck) in distilled water (pH 7.4). Cells were taken up in DMEM/HAMF10, 10% (v/v) fetal calf serum (FCS) (PAA, Pasching, Austria) and 1% (v/v) penicillin/streptomycin-glutamine (Invitrogen) supplemented with 25ng/mL of granulocyte-macrophage colonystimulating factor (GM-CSF) (Immunotools, Friesoythe, Germany) and cultured in a 5% CO2-humifided incubator at 37⁰C.
After 5-7 days in culture, microglia were activated with highly purified recombinant human HspB5 (Delta Crystallon BV, Leiden, The Netherlands; 50µg/mL) or polyinosinic-polycytidylic acid (poly(I:C; InvivoGen, 50 µg/mL). Polarization into different activation phenotypes was achieved by treatment for 2h with 10ng/mL IFNγ (U-Cytech, Utrecht, The Netherlands) followed by addition of 10ng/mL LPS for 2h (InvivoGen, San Diego, CA), or with 10ng/mL IL-4 (Immunotools) for 4h.
Real-Time PCR
Total RNA was isolated from human microglia or mouse tissues using TRIzol (LifeTechnologies, Bleiswijk, The Netherlands) according to manufacturer's protocol. RNA purity and concentrations were measured using a NanoDrop ND-1000 spectrophotometer (ThermoScientific, Wilmington, USA). Reverse Transcription System (Promega) was used to obtain cDNA. Subsequently, a realtime quantitative polymerase chain reaction was performed using sybrgreen (Biorad, Veenendaal, The Netherlands). Gene expression was normalized to the reference genes elongation factor 1α (EF1α) for human material, and to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) for mice material.
The efficiency (E) of primer pairs was determined using LinRegPCR software 36 and relative expression was calculated as E -CT target gene /E -CT reference gene expressed in arbitrary units (AU). Primer sequences and annealing temperatures are listed in Table 2 . To determine PCR product-specificity, melting curves and gel electrophoresis were routinely performed (data not shown).
Table 2. Primer sequences
Enzyme-Linked Immunosorbent Assay
Enzyme Linked Immunosorbent Assay (ELISA) kits from R&D (Abingdon, UK) and Hycult (Uden, The Netherlands) were used according to the manufacturers' protocol to determine PTX3 levels in CSF and plasma samples from MS and control donors [Supporting Information Table 1C] , and in culture supernatants of human microglia. CSF samples and plasma from the same patient were collected at PM and stored as aliquots to avoid freeze thawing.
Statistical analysis
Statistical evaluation of data was performed using GraphPad Prism software 6.0 (GraphPad Software, San Diego, CA). To compare expression levels of different stimulated microglia and clinical EAE scores were assessed by a Mann-Whitney U test. The day of onset and disease incidence was assessed using Kaplan-Meier using SigmaStat software (SPSS). Group EAE score represents the maximal neurological deficit of all animals within the group, and mean EAE score represents the maximal neurological deficit developed by mice with EAE 33, 35 . p values < 0.05 were considered significant.
Results
PTX3 expression during development of MS lesions
We examined PTX3 expression in MS white matter lesions that were classified as either preactive (n=27), active (n=6), chronic active (n=5), or inactive (n=2) according to the degree of myelin integrity and microglia activation, as described previously 23, 26, 28, 37 . We additionally examined leukocortical lesions (n=5) that span the white and grey matter. In preactive lesions that are characterized by the appearance of clusters of HLA-DR + activated microglia in fully myelinated NAWM ( Figure 1A and B) , all activated microglia were found to express markedly elevated levels of PTX3 (Figure1 C-E) . In actively demyelinating MS lesions and along the rim of chronic active lesions ( Figure 1F ), HLA-DR + foamy macrophages/ microglia ( Figure 1G ) also express PTX3, albeit with variable intensity (Figure 1H-J) . Examination of these lesions at higher magnification strongly suggested that these different intensities of PTX3 expression may correlate with the extent of myelin phagocytosis, with higher levels of PTX3 seen in cells that were more avidly engaged in myelin phagocytosis ( Figure 1K -M) as shown by ORO positivity in macrophages/microglia in active lesions (Supplementary Figure 1) . Cells in preactive lesions did not contain ORO+ neutral lipids (Supplementary Figure 1) . In inactive MS lesions containing GFAP + gliotic astrocytes, a limited number of such GFAP + astrocytes were found to express PTX3 as well ( Figure 1N-P) . In leukocortical lesions, PTX3 was only expressed by microglia in the white matter (data not shown). In addition PTX3 was also expressed by endothelial cells in tissue samples containing MS lesions from all stages ( Figure 1I 
PTX3 is undetectable in human cerebrospinal fluid
We next examined whether PTX3 would also be detectable as a free soluble factor in the CSF collected post-mortem, and whether its levels correlated with lesion activity. CSF samples and plasma were collected at PM, thus allowing direct comparisons of samples from the same patients. Samples were stored as aliquots to avoid freeze thawing. While PTX3 was detectable in plasma samples of 3 MS cases (case 10: 1404pg/mL; case 30: 127.7pg/mL; case 33: 47.87pg/mL) and 3 control samples (control 54: 339.6pg/mL; control 56: 455.1pg/mL; control 66: 173.2pg/mL), PTX3 was not detectable in any of the CSF samples from 22 MS cases and 18 control subjects [lower limit of detection of ELISA for PTX3 = 0.04ng/mL (Hycult) or 0.116ng/mL (R&D)] To examine whether this apparent absence of PTX3 from CSF samples could be explained by degradation following release, CSF samples were spiked with 25ng/mL purified recombinant PTX3 protein and incubated for varying periods of time at 37°C. At all time points examined (0, 10, 20, 60 and 120 min), PTX3 remained readily detectable at its initial spike concentration of 25.8 ± 1.3ng/mL. Thus, our inability to detect PTX3 in post-mortem CSF samples is unlikely to have been caused by degradation of PTX3.
PTX3 is differentially induced by TLR ligands
To evaluate which signalling pathways in microglia are the most efficient in promoting PTX3 expression, we exposed cultured human adult microglia to various stimuli and examined levels of PTX3-encoding transcripts. Given previous reports on PTX3 induction following TLR activation [5] [6] [7] 29, 30 we tested agonists for TLR2, TLR3 and TLR4. In addition, we compared the PTX3 transcript response to conditions that favour development of either the classical (pro-inflammatory) M1 state of activation of microglia and macrophages, or the alternative (antiinflammatory) M2. Transcript levels were evaluated after 4h of stimulation in six separate microglial cultures. This time point was established as being optimal for the present evaluation in separate preparatory studies, which were also used to define the optimal dose of activating factors (data not shown). In line with previous data 30 , activation of microglia with the TLR2 agonist HspB5 led to a 50-fold increase in PTX3 transcripts above unstimulated cells, as illustrated in Figure 2 .
Yet, by far the strongest induction of PTX3 transcripts was observed after exposure to the TLR3 agonist poly I:C, which triggered a 125-fold increase. The TLR4 agonist LPS, combined with IFNγ, led to a 20-fold increase, while exposure to the cytokine IL-4 that promotes alternative activation did not induce any increase in PTX3 levels. Fully in line with previous reports, TLR engagement is an important activating signal for PTX3 production by human microglia. Alternative activation of microglia by IL-4, on the other hand, does not appear to deliver a relevant signal in this context.
Lack of PTX3 does not affect EAE induction
To examine the role of PTX3 in EAE, PTX3-deficient mice were immunized with MOG in CFA. No significant difference was observed between WT, heterozygous and PTX3-deficient mice with regard to day of onset (WT vs HE P=0.5; KO vs HE P= 0.13; KO vs WT P=0.53) or time to reach maximum clinical score (WT vs HE P=0.55; KO vs HE P= 0.15; KO vs WT P=0.0.92) ( Figure 3A) . We also examined the effects of PTX3 on the histopathology of the animals at the end of the 28-day EAE experiment. No differences were observed in the extent of myelin damage or CD3 + T-cell infiltration in either WT, PTX3-deficient, or heterozygous mice (Figure 3B-D;) . Except from the PTX3-deficient mice, all animals showed marked PTX3 expression in the subpial regions in the spinal cord ( Figure 3B2,C2) , where PTX3 co-localized with iba1 + microglia ( Figure 3E ). In contrast, GFAP + astrocytes in these regions only occasionally expressed PTX3 ( Figure 3F ) and PTX3 expression was not observed in the grey matter (data not shown). That elevated PTX3 expression in microglia during EAE reflects a local response to inflammation was confirmed by comparing PTX3 transcript levels in the spinal cord to those in spleens. As shown in Figure 3G , transcripts in the spinal cord of WT and heterozygous mice were significantly higher than in spleen (WT p=0.0043; HE p=0.0159).
Administration of PTX3 does not influence acute EAE in Biozzi ABH mice
To examine whether PTX3 can act as a protective factor during acute EAE, ABH mice were administered intravenously with 100µg recombinant glycosylated human recombinant PTX3 on days 10, 12, 14 after immunization for EAE induction yet prior to onset of acute EAE. This dosing regimen using recombinant human PTX3 has been previously shown to be effective in acute lung injury in mice 38 . All vehicle-treated (n=10) and PTX3-treated animals (n=10) developed EAE ( Figure  4A ) and this progressed to grade 4.0 acute EAE, which was an endpoint ( Figure  4B Thus, exogenous PTX3 did not significantly affect the course of EAE when administered in the frequency and with this dose. In contrast the induction of immunological tolerance with T cell depletion and intravenous myelin-antigen administration inhibited the development of EAE in most animals ( Figure 4A in CFA by a subcutaneous injection. Pertussis toxin was injected intraperitoneally at the day of immunization and again two days later. EAE scores were recorded daily by an investigator blinded to group identity and presented in a graph, data are shown as mean ±SEM. No significant difference was observed between the groups with regard to day of onset of EAE or time to reach maximum clinical score (A). Spinal cord tissue from 4 WT, 6 KO and 4 HE mice were used for immunohistopathological studies. Sections were imunolabelled with antibodies directed against PLP (B1-D1), PTX3 (B2-D2) and CD3 (B3-D3). Double labelling of PTX3 with iba-1 showed colocalization (E), while only occasional GFAP+ astrocytes were double labelled with PTX3 (F). mRNA from spinal cord and spleen tissue (4 WT, 4 KO and 3 HE mice) was extracted and used for qPCRanalysis of PTX3 transcript levels. Data are presented relative to GAPDH and as mean ±SEM, derived from 2 independent experiments (G). Scale bar =10µm. Images are representative of 2 independent experiments. *p≤0.05,**p≤ 0.01 (pairwise comparison, Mann-Whitney U test) Discussion PTX3, a long pentraxin locally induced during inflammation, is an acute-phase protein with diverse functions. In this study, we examined its role during autoimmune neuroinflammation, inspired by our recent finding that PTX3 is strongly induced in cultured human microglia by HspB5, an endogenous TLR2 agonists that accumulates in the CNS during MS. HspB5 has broad neuroprotective and anti-inflammatory effects, and inhibits experimental neuroinflammation in mice [39] [40] [41] [42] , as well as disease activity in MS patients. Given the diverse functions of PTX3, we aimed to clarify to what extent it could play a role in these protective properties of HspB5.
In line with previous reports that have documented a prominent role of PTX3 in regulating phagocytosis, the expression pattern of PTX3, especially in active demyelinating MS lesions, strongly suggests an association between local production of PTX3 and active phagocytosis during demyelination in MS. PTX3 expression was consistently the strongest in so-called 'foamy' macrophages/microglia, that are prominently engaged in myelin phagocytosis. Despite such marked local expression, PTX3 was not detectable in any of the CSF samples from MS patients we examined, and in only 3 of 22 plasma samples. These data emphasize that PTX3 expression in the CNS is a strictly localized As a positive control myelin-specific immunological tolerance was induced by injection of CD4-T cell depleting mAb together with intravenous SCH coupled splenocytes (dash and dot line) as previously described [44] . phenomenon, and do not support the likelihood that it can be used as a biomarker for disease activity in MS, as suggested by a previous report claiming that plasma levels of PTX3 correlate with relapses during MS 21 . Marked expression of PTX3 in the clustered, activated microglia that form preactive lesions is another novel finding in the present study. The fact that PTX3 is induced in these preactive MS lesions in the absence of blood-brain barrier damage or leukocyte infiltration clarifies that its expression in microglia in this context is triggered by endogenous factors within the CNS itself. One of these factors may well be HspB5, which is produced by stressed oligodendrocytes in such preactive lesions, and activates microglia as a TLR2 agonist 30 . In line with previous data, the response profile of cultured human adult microglia (Fig. 2) confirms that engagement of TLR is an effective way to induce PTX3 expression in these cells, with TLR3 engagement as the most effective trigger. Microbial infection is a major threat to the CNS, which rationalizes the apparent propensity of microglia to produce large amounts of PTX3 in response to engagement of TLRs that sense microbial pathogens. Our data additionally suggest that PTX3 expression in microglia is not associated with the differentiation of these cells into classically or alternatively activated phagocytes. Given that no active myelin phagocytosis is ongoing in preactive MS lesions, PTX3 in these lesions does not play any role in promoting myelin uptake as it appears to do in active lesions. In the absence of any other obvious function of PTX3 in preactive MS lesions, its induction in this context may simply be a reflection of overlapping intracellular signalling pathways that are activated in microglia in preactive as well as active lesions.
Another CNS location of prominent PTX3 induction during MS includes brain endothelial cells, in which PTX3 was readily detectably by immunohistochemical staining of both active and chronic active lesions. While PTX3 was clearly associated with endothelial cells it is unclear whether this reflects binding of microglial PTX3 to these cells, or endogenous production of PTX3 by endothelial cells themselves. Given that PTX3 stimulates angiogenesis after cerebral ischemia, PTX3 may well play a similar role in MS since increased vascular density and endothelial cell proliferation has been described in MS lesions 43 . Whether angiogenesis aids influx of pathogenic cells into the CNS in MS is as yet unknown but indicates that treatment strategies blocking PTX3 may decrease clinical and pathological signs of disease. In preactive lesions, on the other hand, endothelial PTX3 was not observed since these early lesions are not associated with blood vessels 26 . This suggests that PTX3 induction in endothelial cells is more prominently driven by soluble inflammatory mediators that are released within actively demyelinating lesions rather than by TLR ligation as in microglia. That differential pathways exist for PTX3 induction in different types of cells is supported by previous reports. IL-1β released during experimental stroke for example effectively induces PTX3 expression in neurons and astrocytes, but fails to do the same in microglia and infiltrated macrophages 12 . The significance of endothelial PTX3 expression during neuroinflammation, however, remains to be established. PTX3 was recently shown to induce endothelial cell proliferation 12 . On the other hand, PTX3 can also bind to the pro-angiogenic factor FGF2, thus inhibiting angiogenesis. Furthermore, PTX3 can bind to P-selectin, potentially inhibiting leukocyte migration. Neither of these possible effects emerged as an obvious difference between PTX3-deficient and WT mice during the course of EAE. It remains conceivable, however, that the effects of PTX3 only play a role at later stages of recovery and tissue repair following neuroinflammation, similar to what had been described for the role of PTX3 in cerebral ischemia 12 . When taken together, our data show that already in very early stages of neuroinflammation during MS, PTX3 is induced in microglia, most likely by endogenous TLR ligands such as HspB5. PTX3 expression persists in microglia/macrophages in full-blown demyelinating lesions, and is especially prominent in cells that are actively engaged in myelin phagocytosis. Additional expression occurs in endothelial cells and some gliotic astrocytes in later-stage MS lesions. Its production remains a local phenomenon, and PTX3 does not appear in meaningful quantities in the CSF. In contrast to studies showing that the short pentraxins CRP and SAP protect against EAE in C57BL/6 mice 44,45 therapeutic administration of exogenous PTX3 does not influences its clinical course. Whether this is due to the inability of recombinant PTX3 to penetrate the CNS is unknown. However, PTX3 deficiency does not modulate clinical signs of EAE or histopathological features in any significant way.
While these data are consistent with a local role of PTX3 in promoting myelin phagocytosis by activated microglia and macrophages during MS and EAE, they do not point to a major role of PTX3 in regulating inflammatory pathways during the early stages of autoimmune neuroinflammation. Given recent reports on an important role of PTX3 in recovery and tissue repair following cerebral ischemia rather than a role in the development of ischemic damage 12 , it is useful to emphasize that our data do not exclude a similar role for PTX3 in recovery and repair at later stages of autoimmune neuroinflammation.
